Novartis AG (NVS) Competitors & Peers
The 5 largest companies in the same industry as Novartis AG, by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| LLY | Peer | $1,183.46 | P/E 39.7RSI 56Cap 1.06 T |
| JNJ | Peer | $271.22 | P/E 31.3RSI 55Cap 650.3 B |
| ABBV | Peer | $264.34 | P/E 74.3RSI 58Cap 466.4 B |
| MRK | Peer | $148.78 | P/E 118.9RSI 58Cap 366.6 B |
| AZN | Peer | $166.58 | P/E 25.2RSI 59Cap 261.4 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- REGNCompetitor
Novartis competes directly in the ophthalmology space (e.g., Lucentis and Beovu) against Eylea.
Model-inferred, unverified — treat as a lead, not evidence - ALNYPartner
Alnylam-Novartis Leqvio (inclisiran) for hypercholesterolemia.
Model-inferred, unverified — treat as a lead, not evidence - ERASPartner
Erasca co-develops combinations with Novartis MEK inhibitors.
Model-inferred, unverified — treat as a lead, not evidence - OCSPartner
Oculis in-licensed OCS-02 (licofelanem) TNF-alpha antibody droplet tech from Novartis.
Model-inferred, unverified — treat as a lead, not evidence - VERACompetitor
Vera's atacicept competes with Novartis's pipeline therapies for IgA nephropathy treatment.
Model-inferred, unverified — treat as a lead, not evidence - VEEVSupplier
Novartis uses Veeva Vault as a primary clinical/regulatory platform.
Model-inferred, unverified — treat as a lead, not evidence